Published in

Springer Nature [academic journals on nature.com], Bone Marrow Transplantation, 2(52), p. 216-221, 2016

DOI: 10.1038/bmt.2016.213

Links

Tools

Export citation

Search in Google Scholar

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Journal article published in 2016 by E. Van Den Neste, N. Schmitz, N. Mounier, D. Gill, D. Linch, M. Trneny ORCID, R. Bouadballah, John A. Radford, M. Bargetzi, V. Ribrag, U. Dührsen, D. Ma, J. Briere, C. Thieblemont, E. Bachy ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed 2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting